世界の医療・医薬品産業レポート

TOP  >  医療機器レポート  >  ドラッグ・デリバリー・システム  >  注射可能ドラッグデリバリー - 医療機器パイプライン評価 2018年

注射可能ドラッグデリバリー - 医療機器パイプライン評価 2018年
Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018

レポートタイトル 注射可能ドラッグデリバリー - 医療機器パイプライン評価 2018年
出版社名 GlobalData
発刊日 2018-04-01
体裁 PDF / 607 ページ
シングルユーザ価格 US$ 4,000
レポート分類 医療機器レポート
地域 グローバル
領域 ドラッグ・デリバリー・システム
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の医療機器開発についての包括的情報、さまざまな開発ステージでの比較分析、パイプライン製品開発における主要企業のレビュー、主な機器の治験段階、治験実施状況、治験開始および終了日、治験数などの情報を提供します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 14
1.2 List of Figures 21
2 Introduction 22
2.1 Injectable Drug Delivery Overview 22
3 Products under Development 23
3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development 23
3.2 Injectable Drug Delivery - Pipeline Products by Segment 24
3.3 Injectable Drug Delivery - Pipeline Products by Territory 25
3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path 26
3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 27
3.6 Injectable Drug Delivery - Ongoing Clinical Trials 28
4 Injectable Drug Delivery - Pipeline Products under Development by Companies 29
4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 29
4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development 32
5 Injectable Drug Delivery Companies and Product Overview 35
5.1 3M Co Company Overview 35
5.2 Adamis Pharmaceuticals Corp Company Overview 36
5.3 AdrenaCard, Inc. Company Overview 37
5.4 Allergan Inc Company Overview 38
5.5 Alsensa ApS Company Overview 39
5.6 Antares Pharma Inc Company Overview 40
5.7 Aquavit Pharmaceuticals Inc Company Overview 43
5.8 Artemes Technologies, Inc. Company Overview 44
5.9 Ascendis Pharma A/S Company Overview 45
5.10 Ascil Proyectos SL Company Overview 48
5.11 ASIS Corp Company Overview 49
5.12 AstraZeneca Plc Company Overview 52
5.13 AzureBio SL Company Overview 53
5.14 Becton Dickinson and Co Company Overview 54
5.15 BioCorRx Inc Company Overview 56
5.16 BioMarin Pharmaceutical Inc Company Overview 58
5.17 BioRestorative Therapies Inc Company Overview 59
5.18 Bioxis Pharmaceuticals Company Overview 60
5.19 BTG Plc Company Overview 61
5.20 Burke Pharmaceuticals LLC Company Overview 62
5.21 Callisyn Biomedical Inc Company Overview 63
5.22 Cambridge Consultants Ltd Company Overview 64
5.23 Case Western Reserve University Company Overview 65
5.24 Cincinnati Children's Hospital Medical Center Company Overview 66
5.25 Clearside BioMedical Inc Company Overview 67
5.26 Consort Medical plc Company Overview 71
5.27 DALI Medical Devices Ltd. Company Overview 74
5.28 Delcath Systems Inc Company Overview 77
5.29 DelSite, Inc. (Inactive) Company Overview 80
5.30 Elcam Medical Company Overview 81
5.31 EmboMedics Inc Company Overview 85
5.32 Emergent BioSolutions Inc Company Overview 87
5.33 Eveon SAS Company Overview 90
5.34 FHC Inc Company Overview 92
5.35 GeneSYS-ID Inc Company Overview 93
5.36 Ghent University Company Overview 94
5.37 Inovio Pharmaceuticals Inc Company Overview 95
5.38 InVivo Therapeutics Corp Company Overview 97
5.39 Ipsen SA Company Overview 98
5.40 kaleo Inc Company Overview 99
5.41 LyoGo Company Overview 100
5.42 Meridian Medical Technologies Inc Company Overview 101
5.43 Mertiva AB Company Overview 102
5.44 Milestone Scientific Inc Company Overview 103
5.45 Novo Nordisk AS Company Overview 111
5.46 Novosanis NV Company Overview 112
5.47 Osteo Pharma BV Company Overview 113
5.48 Oval Medical Technologies Ltd Company Overview 114
5.49 Particle Therapeutics Ltd Company Overview 115
5.50 Pfizer Inc Company Overview 116
5.51 Portal Instruments Inc Company Overview 118
5.52 pSivida Corp Company Overview 119
5.53 Queen Elizabeth Hospital Company Overview 127
5.54 QuiO Technologies LLC Company Overview 128
5.55 RepliCel Life Sciences Inc Company Overview 130
5.56 Rescitech Vision Pvt Ltd Company Overview 131
5.57 RetinaPharma Technologies Inc Company Overview 132
5.58 Roche Diagnostics International Ltd Company Overview 133
5.59 Scandinavian Health Ltd Company Overview 136
5.60 Sun Pharma Advanced Research Company Ltd Company Overview 137
5.61 TCB medical devices Company Overview 138
5.62 Terumo Corp Company Overview 139
5.63 Teva Pharmaceutical Industries Ltd Company Overview 141
5.64 TheraKine Inc (Inactive) Company Overview 143
5.65 Twin Star Medical Inc Company Overview 144
5.66 Unilife Corporation Company Overview 145
5.67 University of Calgary Company Overview 148
5.68 University of California San Diego Company Overview 149
5.69 University of California San Francisco Company Overview 151
5.70 University of Delaware Company Overview 152
5.71 University of Dundee Company Overview 153
5.72 University of Florida Company Overview 154
5.73 University of Saskatchewan Company Overview 156
5.74 University of Texas at Austin Company Overview 157
5.75 Vanderbilt University Company Overview 158
5.76 West Pharmaceutical Services Inc Company Overview 159
5.77 Windgap Medical Inc Company Overview 160
5.78 XERIS Pharmaceuticals Inc Company Overview 161
5.79 Ypsomed Holding AG Company Overview 162
6 Injectable Drug Delivery- Recent Developments 163
6.1 Mar 08, 2018: Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology 163
6.2 Mar 06, 2018: Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization 163
6.3 Mar 06, 2018: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 164
6.4 Mar 06, 2018: Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs 164
6.5 Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 165
6.6 Mar 02, 2018: FDA to Review DUPIXENT (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma 165
6.7 Mar 02, 2018: Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis 166
6.8 Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer 167
6.9 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 167
6.10 Feb 28, 2018: Catalent Completes $4.6 Million Expansion at Singapore Facility 169
6.11 Feb 27, 2018: Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta (pegfilgrastim) 169
6.12 Feb 26, 2018: West Names Silji Abraham Chief Digital And Transformation Officer 170
6.13 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 171
6.14 Feb 26, 2018: Recipharm: Chief Financial Officer to leave Recipharm 172
6.15 Feb 25, 2018: Dr. Reddy’s Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 172
6.16 Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 172
6.17 Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 172
6.18 Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results 176
6.19 Feb 22, 2018: Recipharm Reports Fourth Quarter And Full Year 2017 179
6.20 Feb 21, 2018: United Therapeutics Reports 2017 Fourth Quarter And Annual Financial Results 180
6.21 Feb 21, 2018: Merck Invests Additional ?40 Million to Enhance Manufacturing and Distribution in Asia 182
6.22 Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 183
6.23 Feb 20, 2018: Catalent Announces Changes to its Board of Directors 184
6.24 Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit 185
6.25 Feb 15, 2018: West Announces Fourth-Quarter and Full-Year 2017 Results and Announces Quarterly Dividend 185
6.26 Feb 14, 2018: Antares Pharma Announces FDA Approval of Partners Product Utilizing Our QuickShot Auto Injector 187
6.27 Feb 14, 2018: Alkermes Names Shane Cooke As Board Director 188
6.28 Feb 14, 2018: Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017 188
6.29 Feb 14, 2018: Recipharm Appoints President Development Services to Drive End to End Offering 190
6.30 Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results 191
6.31 Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102 193
6.32 Feb 08, 2018: First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent, now available in Canada 194
6.33 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 195
6.34 Feb 07, 2018: SelfDose Patient-Controlled Injector Named as Recipient of Pharmapack Exhibitor Innovation Award 203
6.35 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 204
6.36 Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 206
6.37 Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard 207
6.38 Feb 06, 2018: Covestro plastic enables medical device innovation 208
6.39 Feb 06, 2018: MRI Interventions Announces Record 629 ClearPoint Cases in 2017 209
6.40 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany 210
6.41 Feb 05, 2018: Catalent Reports Second Quarter Fiscal 2018 Financial Results 210
6.42 Feb 02, 2018: Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe 214
6.43 Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 214
6.44 Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results 216
6.45 Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 221
7 Appendix 602
7.1 Methodology 602
7.2 About GlobalData 605
7.3 Contact Us 605
7.4 Disclaimer 605

1.2 List of Figures
Figure 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
Figure 2: Injectable Drug Delivery - Pipeline Products by Segment 25
Figure 3: Injectable Drug Delivery - Pipeline Products by Territory 26
Figure 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
Figure 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
Figure 6: Injectable Drug Delivery - Ongoing Clinical Trials 29

1.1 List of Tables
Table 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
Table 2: Injectable Drug Delivery - Pipeline Products by Segment 25
Table 3: Injectable Drug Delivery - Pipeline Products by Territory 26
Table 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
Table 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
Table 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
Table 7: Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 30
Table 8: Injectable Drug Delivery - Pipeline Products by Stage of Development 33
Table 9: 3M Co Pipeline Products & Ongoing Clinical Trials Overview 36
Table 10: 3M Hollow Microstructured Transdermal System - Product Status 36
Table 11: 3M Hollow Microstructured Transdermal System - Product Description 36
Table 12: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 37
Table 13: Symjepi - Junior Version - Product Status 37
Table 14: Symjepi - Junior Version - Product Description 37
Table 15: AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
Table 16: Adrenacard Auto-Injector - Product Status 38
Table 17: Adrenacard Auto-Injector - Product Description 38
Table 18: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 39
Table 19: NOVADUR Intravitreal Implant - Product Status 39
Table 20: NOVADUR Intravitreal Implant - Product Description 39
Table 21: Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview 40
Table 22: SQJCT - Product Status 40
Table 23: SQJCT - Product Description 40
Table 24: Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 25: QuickShot Testosterone (QST) - Product Status 41
Table 26: QuickShot Testosterone (QST) - Product Description 41
Table 27: Teva Pen 1 - Product Status 42
Table 28: Teva Pen 1 - Product Description 42
Table 29: Vibex EPI - Product Status 42
Table 30: Vibex EPI - Product Description 42
Table 31: Vibex QS M - Product Status 43
Table 32: Vibex QS M - Product Description 43
Table 33: Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 34: PITO-001 - Product Status 44
Table 35: PITO-001 - Product Description 44
Table 36: Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
Table 37: Artemes Magnetic Injection System - Product Status 45
Table 38: Artemes Magnetic Injection System - Product Description 45
Table 39: Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview 46
Table 40: TransCon hGH Auto-Injector - Product Status 46
Table 41: TransCon hGH Auto-Injector - Product Description 46
Table 42: Ascendis Pharma A/S - Ongoing Clinical Trials Overview 47
Table 43: TransCon hGH Auto-Injector - A Multicenter, Phase III, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children with Growth Hormone Deficiency (GHD) 48
Table 44: Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview 49
Table 45: Prefilled Device - Product Status 49
Table 46: Prefilled Device - Product Description 49
Table 47: ASIS Corp Pipeline Products & Ongoing Clinical Trials Overview 50
Table 48: Automatic Subdermal Injection System - Product Status 50
Table 49: Automatic Subdermal Injection System - Product Description 50
Table 50: ASIS Corp - Ongoing Clinical Trials Overview 51
Table 51: Automatic Subdermal Injection System - ASIS for Botox in Chronic Migraine 52
Table 52: Automatic Subdermal Injection System - ASIS for Botox in Upper Limb Spasticity 52
Table 53: Automatic Subdermal Injection System - ASIS for Enbrel in Plaque Psoriasis 52
Table 54: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 53
Table 55: Bydureon BCise Autoinjector Device - Product Status 53
Table 56: Bydureon BCise Autoinjector Device - Product Description 53
Table 57: AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview 54
Table 58: Injectable Needle - Product Status 54
Table 59: Injectable Needle - Product Description 54
Table 60: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 55
Table 61: BD Intevia Disposable Autoinjector - Product Status 55
Table 62: BD Intevia Disposable Autoinjector - Product Description 55
Table 63: BD Libertas Wearable Injector - Product Status 56
Table 64: BD Libertas Wearable Injector - Product Description 56
Table 65: T2 Patch Wearable Injector - Product Status 56
Table 66: T2 Patch Wearable Injector - Product Description 56
Table 67: BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview 57
Table 68: Injectable Naltrexone Implant - BICX101 - Product Status 57
Table 69: Injectable Naltrexone Implant - BICX101 - Product Description 57
Table 70: Naltrexone Implant - BICX102 - Product Status 58
Table 71: Naltrexone Implant - BICX102 - Product Description 58
Table 72: BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 59
Table 73: Pegvaliase Pre-filled Syringe - Product Status 59
Table 74: Pegvaliase Pre-filled Syringe - Product Description 59
Table 75: BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 76: Curved Needle Device - Product Status 60
Table 77: Curved Needle Device - Product Description 60
Table 78: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 61
Table 79: Vaccine Delivery Device - Product Status 61
Table 80: Vaccine Delivery Device - Product Description 61
Table 81: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 62
Table 82: Varithena - Aesthetic Leg Veins - Product Status 62
Table 83: Varithena - Aesthetic Leg Veins - Product Description 62
Table 84: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 63
Table 85: BURKE201 Needle Injection Pen - Product Status 63
Table 86: BURKE201 Needle Injection Pen - Product Description 63
Table 87: Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 64
Table 88: TACEspheres Drug Eluting Embolic Microspheres - Product Status 64
Table 89: TACEspheres Drug Eluting Embolic Microspheres - Product Description 64
Table 90: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 65
Table 91: Flexi-ject - Product Status 65
Table 92: Flexi-ject - Product Description 65
Table 93: Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview 66
Table 94: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Status 66
Table 95: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Description 66
Table 96: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 67
Table 97: Pre-Filled Syringe With Flush - Product Status 67
Table 98: Pre-Filled Syringe With Flush - Product Description 67
Table 99: Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 68
Table 100: SCS Microinjector - Product Status 68
Table 101: SCS Microinjector - Product Description 68
Table 102: Clearside BioMedical Inc - Ongoing Clinical Trials Overview 69
Table 103: SCS Microinjector - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-infectious Uveitis 70
Loading....